Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Rating the Strength of Evidence From the CER: A Modification of the GRADE Methodology
To determine the strength of the evidence identified in the systematic review, researchers used the grading process outlined for Evidence-based Practice Centers in version 1.0 of the Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews that is based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system of the GRADE Working Group. This system uses four required domains — risk of bias, consistency, directness, and precision — for assessments. All assessments were made by two investigators who resolved disagreements through discussion. The strength of evidence pertaining to each key research question of the CER is classified into four broad categories or grades:
High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
Low: Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of effect and is likely to change the estimate.
Insufficient: Evidence is either unavailable or does not permit estimation of an effect.
Keywords: CF | HGH | human growth hormone | recombinant human growth hormone | rhGH | Strength of Evidence | cystic fibrosis
- Guyatt GH, Oxman AD, Vist GE, et al, for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
- Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research quality and the effective health-care program. J Clin Epidemiol 2010; 633:513-23.
- Atkins D, Best D, Briss PA, et al, for the GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.